Oncolytic Effect of a Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA in an Osteosarcoma...

Area of Science:

• Oncolytic virotherapy
• Gene therapy
• Cancer research

Background:

• Vesicular stomatitis virus (VSV) has been explored for osteosarcoma treatment.
• Previous studies indicated VSV with microRNA143 (VSV-miRNA143) enhanced antitumor effects in vitro, but within a narrow dose range.
• The in vivo efficacy and synergistic effects of VSV-miRNA143 in osteosarcoma models remained unevaluated.

Purpose of the Study:

• To evaluate the in vivo oncolytic effect of VSV-miRNA143 on osteosarcoma.
• To compare the antitumor efficacy of different administration routes (intravenous vs. intratumoral) of VSV-miRNA143 against standard VSV.

Main Methods:

• A recombinant VSV incorporating tumor-suppressor microRNA143 (rVSV-miR143) was developed.
• Comparative analysis of primary tumor volume, metastatic lesions, and survival rates in osteosarcoma mouse models.
• Evaluation of both intratumoral and intravenous administration of rVSV-miR143.

Main Results:

• Intratumoral administration of rVSV-miR143 led to a significant reduction in primary tumor volume compared to VSV.
• No significant differences in metastatic lesions or survival rates were observed between rVSV-miR143 and VSV following intratumoral injection.
• Intravenous administration of rVSV-miR143 showed no significant difference in primary tumor volume, metastatic lesions, or survival rates compared to VSV.

Conclusions:

• VSV incorporating tumor-suppressor microRNA143 exhibits a mild synergistic antitumor effect in vivo.
• Intratumoral delivery of rVSV-miR143 shows potential for primary tumor volume reduction in osteosarcoma.
• Further optimization is needed to enhance the impact on metastasis and survival rates.